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Abstract: Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites
(e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin
clots (e.g., ε-aminocaproic acid and tranexamic acid); however, they have adverse side effects.
Here, we expressed 60-residue (NH2NAE . . . IEKCOOH) Kunitz domain1 (KD1) mutants of human
tissue factor pathway inhibitor type-2 that inhibit plasmin as well as plasminogen activation. A single
(KD1-L17R-KCOOH) and a double mutant (KD1-Y11T/L17R- KCOOH) were expressed in Escherichia
coli as His-tagged constructs, each with enterokinase cleavage sites. KD1-Y11T/L17R-KCOOH was
also expressed in Pichia pastoris. KD1-Y11T/L17R-KCOOH inhibited plasmin comparably to aprotinin
and bound to the kringle domains of plasminogen/plasmin and tPA with Kd of ~50 nM and ~35 nM,
respectively. Importantly, compared to aprotinin, KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH
did not inhibit kallikrein. Moreover, the antifibrinolytic potential of KD1-Y11T/L17R-KCOOH
was better than that of KD1-L17R-KCOOH and similar to that of aprotinin in plasma clot-lysis
assays. In thromboelastography experiments, KD1-Y11T/L17R-KCOOH was shown to inhibit
fibrinolysis in a dose dependent manner and was comparable to aprotinin at a higher concentration.
Further, KD1-Y11T/L17R-KCOOH did not induce cytotoxicity in primary human endothelial cells or
fibroblasts. We conclude that KD1-Y11T/L17R-KCOOH is comparable to aprotinin, the most potent
known inhibitor of plasmin and can be produced in large amounts using Pichia.
Keywords: aprotinin; ε-aminocaproic acid; tranexamic acid; antifibrinolytics; thromboelastography
1. Introduction
In severe trauma and during major surgical procedures, such as cardiac surgery, the fibrinolytic
system is hyperactivated, resulting in severe hemorrhaging [1–3]. Extensive bleeding poses significant
mortality risks and costs in battlefields, accidents and hospital settings. Uncontrolled bleeding is
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the leading cause of preventable death in trauma and often leads to the need for extensive blood
transfusions during surgeries [4,5]. Antifibrinolytics, by inhibiting fibrinolysis, and thereby fibrin
degradation products, reduce transfusion requirements [6,7]. Aprotinin (bovine pancreatic trypsin
inhibitor, BPTI), a potent inhibitor of the plasmin active site, had been the leading antifibrinolytic
agent to reduce blood loss during cardiac surgery and extremity trauma [8]. However, its use has
been linked to severe side effects, such as kidney damage, myocardial infarction, and strokes [9,10].
Furthermore, aprotinin is of bovine origin, and its anaphylactic potential is a major concern [11].
For these reasons, it was temporarily removed from the clinical market in 2008 [12]. The currently
approved therapeutic agents, tranexamic acid (TXA) and ε-aminocaproic acid (EACA), are lysine
analogues, which avert the binding of plasminogen and tissue plasminogen activator (tPA) to the fibrin
clot [13,14]. As a result, localized activation of plasminogen to plasmin is prohibited and fibrinolysis
is prevented. However, EACA and TXA are not as effective as aprotinin in reducing blood loss [15].
Furthermore, like aprotinin, they also cause kidney failure [16], and recent evidence indicates that
TXA, and to a lesser extent EACA, are associated with a significant incidence of seizures [16,17].
Therefore, an improved antifibrinolytic agent is needed that is devoid of adverse effects of aprotinin
and lysine analogs.
Several active site plasmin inhibitors have been reported in the literature [18–25], but the
development stages of most of them are unknown. Textilinin-1 (Q8008), the Kunitz domain plasmin
active site inhibitor from Pseudonaja textilis [19,26], is under preclinical development. Q8008 inhibits
plasmin with 10- to 15-fold weaker affinity than aprotinin, but it also inhibits kallikrein poorly [19,26].
In a mouse tail bleeding model, Q8008 was reported to be as effective as aprotinin at reducing blood
loss [26]. However, since Q8008 is derived from snake venom, it can cause anaphylactic response
in humans similar to that observed for aprotinin. Moreover, using the scaffold of sunflower trypsin
inhibitor-1, a very potent cyclic peptide active site inhibitor of plasmin was designed with 0.05 nM
Ki; it has been proposed as a candidate for drug development [25]. Additionally, allosteric synthetic
fibrinolytic inhibitors have been proposed to reduce perioperative bleeding, but they are in very
early stages of development [27,28]. Furthermore, a very potent plasmin inhibitor (DX-1000) is being
developed as an antineoplastic agent instead of as an antifibrinolytic agent [29].
Notably, when aprotinin was banned in 2008, the pharmacologic agent ecallantide (DX-88),
which inhibits both kallikrein and plasmin, was clinically evaluated [30]. This study was terminated
prematurely due to an increased mortality observed in the ecallantide arm. Another agent, MDCO2010,
which inhibits plasmin, factor (F) Xa, FXIa and activated protein C (APC), was also clinically
evaluated [31]. This study was terminated prematurely as well due to an increased number of
serious adverse events in the treatment groups. The causes of the safety issues are under investigation.
In the current study, we describe an antifibrinolytic agent which inhibits plasmin with comparable
potency to aprotinin, but which is a very weak inhibitor of kallikrein. It was designed using the Kunitz
domain 1 (KD1) of human tissue factor pathway inhibitor type-2 (TFPI-2) as a scaffold. The new
60-residue plasmin inhibitor, KD1-Y11T/L17R-KCOOH, has one additional mutation with a different
C-terminal lysine (IEKCOOH), compared to the earlier heterogeneous single mutant KD1-L17R with
C-terminal IEKVPK (designated KD1-L17R-KT) [32]. KD1-Y11T/L17R-KCOOH inhibits plasmin better
than the current single mutant KD1-L17R-KCOOH, and in addition to plasmin, it also binds to the
kringle domains of plasminogen and tPA with 35 to 50 nM dissociation constants. It is anticipated
that at a therapeutic dose of 2 µM in plasma, the lowest Hammersmith regime of aprotinin [33],
KD1-Y11T/L17R-KCOOH will inhibit fibrinolysis effectively by inhibiting the plasmin active site as well
as by blocking the binding of plasminogen and tPA to the fibrin clot. Thus, KD1-Y11T/L17R-KCOOH
appears to be a promising candidate to replace aprotinin in clinical settings. Experimental details
comparing aprotinin with KD1-Y11T/L17R-KCOOH are presented herein. Moreover, modeling was
used to evaluate the effect of Tyr11 to Thr mutation as well as IEK at the C-terminus in the TFPI-2
KD1 inhibitor scaffold. Structural information gained from such modeling to delineate the enhanced
antifibrinolytic activity of the mutants is discussed.
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2. Experimental Section
2.1. Materials
Escherichia coli (E. coli) strain BL21(DE3) pLysS and pET28a expression vector were obtained from
Novagen Inc. (Madison, WI, USA). Amicon centrifugal filter devices (3000 Mr cutoff) were purchased
from Millipore (Bedford, MA, USA). QSepharose FF, Superdex 200, and His-Trap HP columns were
obtained from Amersham Biosciences. Diisopropylfluorophosphate (DFP) was from Calbiochem
(San Diego, CA, USA). TXA, EACA, kanamycin and isopropyl thiogalactopyranoside (IPTG) were
obtained from Sigma (St. Louis, MO, USA). Caspase-Glo 3/7 Assay kit and CellTox™Green Cytotoxicity
Assay kit were from Promega (Madison, WI, USA). Purified human FXIa, thrombin (IIa) and plasmin
were purchased from Hematologic Technologies Inc (Essex Junction, VT, USA). Plasma kallikrein
(pKLK) was from Enzyme Research Laboratories (South Bend, IN, USA). Alteplase (tPA) was purchased
from Genentech (South San Francisco, CA, USA). Recombinant enterokinase was from Novogen,
EMD Chemicals (San Diego, CA, USA). Normal pooled plasma (NPP) was purchased from George King
Bio-Medical Inc. (Overland Park, Kansas). δPlasmin (recombinant plasmin containing the protease
domain and the first kringle domain) was obtained from Dr. Victor Marder (University of California,
Los Angeles, CA, USA) and taxol was kindly provided by Dr. Zhenfeng Duan (University of California,
Los Angeles, CA, USA). Aprotinin (BPTI) was received from ZymoGenetics (Seattle, WA, USA),
and human factor VIIa (FVIIa) was prepared as described previously [34]. Soluble tissue factor
(sTF, residues 1-219) was obtained from Tom Girard (Washington University, St. Louis, MO, USA).
Plasmin substrate S-2251 (H-D-Val-Leu-Lys-p-nitroanilide), pKLK, and FXIa substrate S-2366
(pyroGlu-Pro-Arg-p-nitroanilide), and FVIIa substrate S-2288 (H-DIle-Pro-Arg-p-nitroanilide) were
obtained from Diapharma Inc (West Chester, OH, USA). Fresh normal human citrated blood was
bought from Nebraska Medical Center, Omaha. Partial thromboplastin time (PT) and activated partial
thromboplastin time (aPTT) were normal for each blood donor.
2.2. Expression and Purification of KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH in E. coli
The cDNA sequences of KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH with C-terminal IEK
were cloned and overexpressed as amino-terminal His6-tagged fusion proteins in E. coli strain
BL21(DE3) pLysS using the T7 promoter system. The recombinant plasmid derived from pET28a,
containing a His6 leader sequence followed by an enterokinase cleavage site and the cDNA encoding
the KD1-L17R-KCOOH or KD1-Y11T/L17R-KCOOH, was prepared according to standard procedures [35].
The sequences of the constructs expressed are given in Figure 1. The His6-tagged KD1-L17R-KCOOH
and KD1-Y11T/L17R-KCOOH were expressed in E. coli grown in Luria broth containing 15 mg/liter
kanamycin and induced at 37 ◦C with 1 mM IPTG at mid-log phase (A600 ~0.9) for 5–6 h at 37 ◦C.
The His6-tagged KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH were purified from the inclusion
bodies using a nickel-charged His-Trap column. The His-Trap purified proteins were refolded using
the reduced and oxidized glutathione system and further purified using Q-Sepharose FF column as
described previously [32,36].
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Figure 1. The expressed sequences of human TFPI-2 KD1 single mutant (KD1-L17R-KCOOH) in E. coli
and double mutant (KD1-Y11T/L17R-KCOOH) in E.coli and Pichia pastoris. The down arrows indicate
the enterokinase cleavage site introduced to remove the His-tag. The mutated residues Tyr11Thr and
Leu17Arg are marked in red and the enterokinase cleavage sequence introduced is marked in blue.
Residue 1 is numbered according to the BPTI-Kunitz domain numbering and corresponds to the amino
acid 10 in the TFPI-2 Kunitz domain1 sequence.
2.3. KD1-Y11T/L17R-KCOOH Clone Construction and Expression in Pichia pastoris
Pichia pastoris strain X-33 and the secretion expression vector pPICZαA were purchased from
Invitrogen (San Diego, CA, USA). KD1-Y11T/L17R-KCOOH cDNA corresponding to the amino acid
sequence (Figure 1) was synthesized by IDT (Coralville, IA, USA). The cDNA was amplified by
PCR, and the product was linearized and subcloned into XhoI and NotI restriction sites of pPICZαA.
Further vector amplification was carried out in DH5α competent cells. Extracted cDNA was introduced
into P. pastoris X-33 via electroporation with a Bio-Rad Gene Pulser electroporator. The transformants
were plated on YPD plates supplemented with 500 µg zeocin/mL. Colonies were evaluated by
SDS-PAGE for KD1-Y11T/L17R-KCOOH expression in BMM medium. Fermentation inoculation shake
flasks were prepared using buffered minimal glycerol medium (BMGY) pH 6.0. First, a single colony
expressing KD1-Y11T/L17R-KCOOH was inoculated into 50 mL for 12 h, and 0.5 mL of the resulting
culture was transferred to 300 mL BMGY pH 6.0 for 20 h. The latter was then inoculated into a 15 L
NLF BioEngineering Bioreactor (Wald, Switzerland) containing 3 L Basal Salts Medium (BSM) pH 5.0.
Protein expression was induced with methanol and carried out for 48 h at 30 ◦C, pH 5.0 and 40%
dissolved oxygen. Fermentation broth was centrifuged at 7200 rpm at 4 ◦C. Supernatant containing
KD1-Y11T/L17R-KCOOH was collected and stored at −30 ◦C until further processing.
2.4. KD1-Y11T/L17R-KCOOH Purification from Pichia pastoris
One hundred milliliters of fermentation supernatant was adjusted to pH 8.5 and centrifuged for
5 min at 1500 RFC at room temperature. Then, the supernatant was collected and adjusted to pH 3.0
and mixed with 0.5 mL Titron X-100 for 30 min. Urea was added up to a final concentration of 4 M
and incubated for 2.5 h at room temperature. After incubation, the solution was diluted to a final
conductivity of 12 mS. Purification was carried out using Biocad Vision workstation at constant flow
rate of 120 cm/h. Sample was loaded on to a SP-Sepharose (GE Healthcare Bio-Sciences Pittsburgh, PA)
column previously equilibrated with 50 mM Phosphate buffer pH 2.8 (wash buffer). Then, the column
was washed with two column volume wash buffer, and protein was eluted with 50 mM phosphate
buffer, pH 2.8, containing 1.0 M NaCl. The fractions containing KD1-Y11T/L17R-KCOOH were pooled
and supplemented with L-Arginine to 0.5 M and with mannitol to 7%. After 1 h of incubation at
room temperature, it was dialyzed against 10 mM phosphate buffer, pH 8.0, using 3.5 kDa MW cutoff
membrane dialysis tubing (Spectrum, Palisades Park, NJ, USA).
2.5. SDS-PAGE
SDS-PAGE was performed using the Laemmli buffer system [37]. The acrylamide concentration
used was 15%, and the gels were stained with Coomassie Brilliant Blue dye.
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2.6. Protease Inhibition Assay
All reactions were carried out in TBS, pH 7.5 (50 mM Tris-HCl, containing 100 mM NaCl), containing
0.1 mg bovine serum albumin/mL (TBS/BSA) and 2 mM Ca2+ (TBS/BSA/Ca2+, pH 7.5). Each enzyme
(plasmin, pKLK, FXIa or FVIIa/sTF) was incubated with various concentrations (10−1 to 2 × 103 nM) of
KD1-WT, KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH or aprotinin (BPTI) for 1 h at room temperature
in a 96-well microtitration plate (total volume 100 µL/well). A synthetic substrate (5 µL) appropriate
for each enzyme was then added to a final concentration of 1 KM, and residual amidolytic activity was
measured in a Vmax kinetic microplate reader (Molecular Devices, San Jose, CA, USA). The inhibition
constant Ki* was determined using the nonlinear regression data analysis program, Grafit. Data for
aprotinin, KD1-WT, KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH were analyzed with an equation
for a tight-binding inhibitor (Equation (1)), where vi and v0 are the inhibited and uninhibited rates,
respectively, and [I]0 and [E]0 are the total concentrations of inhibitor and enzyme, respectively [38,39].
vi = v0
((











Ki values were obtained by correcting for the effect of substrate according to Beith [38],





2.7. Preparation of DIP-δplasmin
Active-site blocked δplasmin was generated by treating δplasmin with equal volumes of 1 M
Tris-HCl, pH 8.0 and 1 M DFP (final concentration of 1 mM DFP) at room temperature for 20 min,
followed by incubation on ice for several hours. Additional equal volumes of 1M Tris-HCl, pH 8.0 and
1M DFP (final concentration of 2 mM) were added and the reaction was incubated at room temperature
for 20 min and then over night at 4 ◦C. The DFP inhibited δplamsin (DIP-δplasmin) was dialyzed
against 20 mM HEPES pH 7.5, containing 150 mM NaCl and assayed for residual activity using S-2251
synthetic substrate hydrolysis. Based upon the residual activity, >99% of the δplasmin was inactivated.
DIP-δplasmin, when analyzed using SDS-PAGE, revealed no protein degradation.
2.8. KD1-Y11T/L17R-KCOOH Binding to tPA and DIP-δplasmin Using Surface Plasmon Resonance (SPR)
Binding studies were performed on a Biacore T100 flow biosensor (Biacore, Uppsala, Sweden)
at 25 ◦C. DIP-δplasmin (~98% purity using SDS-PAGE) or tPA (>98% purity using SDS-PAGE)
was immobilized on carboxymethyl-dextran flow cell (CM5 sensor chips, GE Healthcare)
using amine-coupling chemistry. Flow cell surfaces were activated with a mixture of
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysulfosuccinimide for 5 min (flow rate
10 µL/min), after which the protein (20 µg/mL in 10 mM sodium acetate, pH 5.5) was placed
upon the surface. Unreacted sites were blocked for 5 min with 1 M ethanolamine. The analyte
KD1-Y11T/L17R-KCOOH (100 to 2000 nM) was perfused through flow cells in HBS-P buffer (20 mM
HEPES, pH 7.4, 100 mM NaCl, 0.005% (v/v) P20) at 10 µL/minute for 6 min. After changing to HBS-P
buffer without the protein, analyte dissociation was monitored for 10 min. Flow cells were regenerated
with HBS-P containing 20 mM EACA. Data were corrected for nonspecific binding by subtracting
signals obtained with the analyte infused through a flow cell without the coupled protein. Binding was
analyzed with BIAevaluation software (Biacore) using a 1:1 binding model. Kd values were calculated
from the quotient of the derived dissociation (kd) and association (ka) rate constants.
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2.9. Fibrinolysis (Clot Lysis) Assay
The method of Sperzel and Huetter [40] was followed with minor modifications as outlined
earlier [32,41]. Briefly, IIa was used to initiate fibrin formation in NPP and the lysis of the formed clot
(fibrinolysis) was induced by simultaneous addition of tPA. Clot formation and lysis were monitored
with a Molecular Devices microplate reader (SPECTRAmax 190) measuring the optical density at
405 nm. Briefly, 10 µL of each test compound (KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH, aprotinin)
or saline control was added to 240 µL of NPP. Two hundred twenty-five microliters of this mixture was
then added to 25 µL IIa and tPA in TBS/BSA containing 25 mM CaCl2. In the 250 µL final volume,
the concentration of IIa was 0.15 µg/mL and that of tPA was 1 µg/mL. Under control conditions (zero tPA
and zero test compound), OD405 increased immediately indicating clotting followed by an extremely
slow decrease, representing fibrinolysis. As clotting was almost complete after 5 min, fibrinolysis
induced by tPA was evaluated as a relative decrease of OD405 up to 60 min. KD1-L17R-KCOOH was
tested at final concentrations from 0.5 µM to 5 µM, while KD1-Y11T/L17R-KCOOH and aprotinin were
tested at final concentrations from 0.5 µM to 3 µM.
2.10. Thromboelastography
The effect of different concentrations of KD1-WT, KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH,
aprotinin or EACA on fibrinolysis was evaluated with thromboelastography (TEG) using a TEG
5000 Thrombelastograph (Haemonetics Corp, Braintree, MA, USA). Each clot formation/lysis assay
contained 300 µL of citrated whole blood, plasmin (1.5 µM final concentration), CaCl2 (10 mM final
concentration) and various concentrations of each antifibrinolytic agent in Ringer’s solution to make
the final volume to 360 µL. Plasmin and CaCl2 were added last to initiate simultaneous clotting
and fibrinolysis. A 1.5 µM plasmin concentration was chosen based on the plasmin effect on the
clot strength and lysis. Each experiment was performed for 180 min to establish the LY60 value.
The thromboelastograph was calibrated each day, and each inhibitor concentration was tested in
duplicate. TEG Analytical Software (version 4.2.2; Haemonetics Corporation, Braintree, MA, USA)
was used to calculate the time to clot initiation (R), maximal clot strength (maximal amplitude (MA),
which was directly related to the shear elastic modulus strength, G), and percent lysis 60 min after MA
(LY60) [42].
2.11. Cytotoxicity Assays
2.11.1. Cells and Culture Conditions
Primary human pooled umbilical vein endothelial cells (HUVEC) were obtained from ATCC.
The cells were maintained in Vascular Cell Basal Medium (ATCC), supplemented with the Endothelial
Cell Growth Kit-BBE (ATCC) and Penicillin-Streptomycin-Amphotericin B (ATCC). Primary human
dermal skin fibroblasts were obtained from LONZA and maintained in Fibroblast Basal Medium
(FBMTM, LONZA, Basel, Switzerland), supplemented with a cocktail of growth factors, fetal bovine
serum and antibiotics (FGMTM-2 SingleQuotsTM, LONZA). All cells were maintained in a humidified
5% CO2 atmosphere at 37 ◦C and were passaged once they reached 80% confluence. All experiments
were performed with cells in the logarithmic growth phase.
2.11.2. Antifibrinolytic Agents (KD1-Y11T/L17R-KCOOH, Aprotinin, EACA and TXA)
Stock solutions of antifibrinolytic agents were prepared in phosphate buffer. For toxicity studies,
cells were seeded into 96- or 24-well cell culture plates at 3500 cells/cm2, and were used for experiments
once they reached 80% confluence. Cells were treated with antifibrinolytic agents for 24 h at the
following concentrations: aprotinin and KD1-Y11T/L17R-KCOOH at 0.1 µM, 1 µM, 10 µM and 30 µM;
EACA at 1 mM, 5 mM, 20 mM, and 60 mM and TXA at 0.2 mM, 2 mM, 10 mM and 30 mM.
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2.11.3. Resazurin Reduction Assay
Resazurin reduction assay (Fisher Scientific) was used to evaluate the potential cytotoxicity of
antifibrinolytic agents toward primary human endothelial cells and skin fibroblasts. The phosphate
buffer that was used to dissolve the samples was included as negative control. The assay was based on
the reduction of the nonfluorescent dye resazurin to the highly fluorescent resorufin by viable cells.
The fluorescent signal is proportional to the number of live cells, since nonviable cells are unable to
reduce the dye and do not produce fluorescent signals. Briefly, cells in 96-well cell culture plates were
treated with different concentrations of antifibrinolytic compounds (as described above). After 24 h,
resazurin reagent was added to each well and the plates were incubated at 37 ◦C for 4 h. Fluorescence
was measured by the FLUOstar Omega Microplate Reader (BMG Labtech, Offenburg, Germany)
using an excitation wavelength of 544 nm and an emission wavelength of 590 nm. Each assay was
done in duplicate, with three replicates each. The viability was evaluated based on comparison with
untreated cells.
2.11.4. Caspase 3/7 Assay
The influence of antifibrinolytic agents on apoptosis in cells was detected using the Caspase-Glo
3/7 Assay kit (Promega). Caspases 3 and 7 were activated in cells that undergo apoptosis. The assay
provided a luminogenic substrate for caspase 3 and 7. Enzymatic activity leads to luminescence,
which is proportional to the amount of caspase activity present. Cells were seeded in 96-well plates
and treated with antifibrinolytic agents or phosphate buffer (solvent control). Taxol was included as a
positive control. After 24 h of treatment, caspase reagent was added to each well, mixed and incubated
for 1 h at room temperature. Luminescence was measured using the FLUOstar Omega Microplate
Reader (BMG Labtech).
2.11.5. Cell Toxicity Assay
Cell toxicity and cell death were evaluated with the CellTox™Green Cytotoxicity Assay (Promega).
This assay measures changes in membrane integrity that occur as a result of cell death. The dye used
in the system is excluded from viable cells but binds to DNA in compromised cells, which results
in a fluorescent signal. We measured cell death in HUVEC and primary fibroblasts treated with
antifibrinolytic agents at four concentrations (as indicated above) with triplicates per concentration in
24-well plates after 24 h of exposure. Hoechst (Thermo Fisher Scientific, Waltham, MA, USA) was used
to stain all nuclei. Images of cells were captured using an inverted microscope (Nicon; Edipse T2000 TE).
Green fluorescent cells (FITC filter) and Hoechst stained cells (DAPI filter) were counted using Image J
software. Fluorescent cells were displayed as a percentage of all cells.
2.12. Statistical Methods
One-way analysis of variance (ANOVA) was used to compare the effect of antifibrinolytic agents in
inhibiting fibrinolysis (KD1-WT, KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH, aprotinin) in the plasma
clot lysis assay. The p values for comparing any two means were computed using post hoc tests
and adjusted for multiple comparisons using Tukey’s adjustment. For the TEG data, Levene’s F-test
revealed that the homogeneity of variance was not met. As such, the Welch’s F-test was used and
Games-Howell post hoc procedure was conducted to determine which pairs of the mean MA and
mean LY60% levels differed significantly. For the cell toxicity assays, collected data sets were analyzed
by ANOVA and individual groups were compared using the Student’s t-test. All experiments were
replicated two or three times, with similar results. Quantitative values are reported as mean ± standard
deviation (SD) or standard error of the mean (SEM), as indicated in the figure legends. Differences were
considered statistically significant at p values of 0.05 or lower. All statistical analyses were performed
using SPSS V27 (IBM Corp., Armonk, NY, USA).
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2.13. Molecular Modeling
The crystal structures of µ-plasmin [43], plasminogen kringle domain1 [14] and wild-type
KD1 [36] were used as templates to model the complexes of KD1-Y11T/L17R-KCOOH with µ-plasmin
and with plasmin kringle domain1. The protocols for modeling these complexes have been described
elsewhere [41,44]. Since the C-terminus residues are disordered in the wild-type KD1 crystal structure,
we used the MODELLER program [45] to build this part of the KD1-Y11T/L17R-KCOOH molecule.
The built models were further refined by subjecting to 1000-step minimization with the harmonic
constraints of 10 kcal.mol−1. Å−2 using the AMBER program [46].
3. Results
3.1. Expression and Purification of KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH in E. coli
The 60-residue His6-tagged KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH were expressed in
E. coli strain BL21 (DE3) pLysS with an enterokinase cleavage site (Figure 1). These constructs are
9-residues shorter at the N-terminus and 3-residues shorter at the C-terminus ending with IEK-COOH
(Figure 1) as compared to the previously expressed KD1-L17R with IEKVPK at the C-terminus
(designated KD1-L17R-KT) [41]. The fusion proteins were refolded and purified using Q-Sepharose FF
column. The purified KD1 mutant proteins were incubated with enterokinase to remove the His6-tag;
however, the cleavage was unsuccessful at 1:50 ratio of enzyme to substrate. The reason for the
unsuccessful His6-tag removal could be the inhibition of enterokinase by KD1 mutants, similar to that
described for the inhibition of enterokinase by aprotinin [47]. The SDS-PAGE analysis of purified
KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH, each containing the enterokinase cleavage site and
His6-tag at the NH2-terminus, is shown in Figure 2.
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Figure 2. SDS-PAGE analysis of TFPI-2 KD1 single and double mutants. Lane 1, molecular weight
(MW) markers; lane 2, reduced E.coli KD1-L17R-KCOOH; lane 3, reduced E.coli KD1-Y11T/L17R-KCOOH;
lane 4, reduced P. pastoris KD1-Y11T/L17R-KCOOH; lane 5, nonreduced E. coli KD1-L17R-KCOOH; lane 6,
nonreduced E. coli KD1-Y11T/L17R-KCOOH; lane 7, nonreduced P. pastoris KD1-Y11T/L17R-KCOOH.
Five µg of protein was loaded in each lane. KD1SM, KD1-L17R-KCOOH; and KD1DM,
KD1-Y11T/L17R-KCOOH.
3.2. xpression and urification of 1- 11 /L17 - H in P. pastoris
Si ce t e is6-tag could not be removed by enterokinase in the E. coli expressed mutants,
we expressed the 60-resid e double mutant KD1-Y11T/L17R-KCOOH using P. pastoris and
purified to homogeneity, as described in the Experimental section. Approximately 50 mg of
D1-Y11T/L17R-KCOOH was purified from 100 mL of culture media. The SDS-PAGE analysis of
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purified P. pastoris KD1-Y11T/L17R-KCOOH is shown in Figure 2. Note that the P. pastoris expressed
KD1-Y11T/L17R-KCOOH was of slightly lower MW compared to the corresponding E. coli expressed
KD1-Y11T/L17R-KCOOH containing the His6-tag and the enterokinase cleavage sequence (Figure 1).
3.3. Inhibition Profile of KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH
Wild-type KD1 (KD1-WT) containing the IIa cleavage site inhibited plasmin with Ki
6.0 ± 0.5 nM [32], Figure 3A. KD1-L17R-KCOOH with the IEK C-terminus containing the enterokinase
cleavage site inhibited plasmin with Ki 0.9 ± 0.1 nM similarly to previously described KD1-L17R-KT
with VPK C-terminal containing the IIa cleavage site [41]. Both E. coli and P. pastoris expressed
KD1-Y11T/L17R-KCOOH inhibited plasmin (Ki 0.59± 0.1) with similar affinities to aprotinin (Ki 0.49 ± 0.1)
(Figure 3A). The Ki values for plasmin inhibition by each inhibitor are provided in Table 1.
Thus, the enterokinase cleavage sequence and the His6-tag did not affect the inhibitory activity.
Further, similar to KD1-L17R-KT [32,41], KD1-Y11T/L17R-KCOOH (present study) weakly inhibited
FVIIa/sTF, FXIa and pKLK with Ki > 3 µM (Figure 3B).J. Clin. Med. 2020, 9, x FOR PEER REVIEW 9 of 25 
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Table 1. Ki values for inhibition of plasmin by KD1-WT, KD1-Y11T-KCOOH, KD1-L17R/Y11T-KCOOH
and aprotinin.
Inhibitor Ki (nM) *
KD1-WT 6 ± 0.5
KD1-L17R-KCOOH 0.9 ± 0.1
KD1-Y11T/L17R-KCOOH (E. coli) 0.59 ± 0.1
KD1-Y11T/L17R-KCOOH (Pichia) 0.59 ± 0.1
Aprotinin 0.4 .
* Ki values represent an average ± SD of three independent measurements.
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3.4. KD1-Y11T/L17R-KCOOH Binding to DIP-δplasmin and tPA
We used SPR to study the binding of KD1-Y11T/L17R-KCOOH to immobilized DIP-δplasmin
(Figure 4A) and tPA (Figure 4B). The kon for binding of DIP-δplasmin to KD1-Y11T/L17R-KCOOH was
1.49 ± 0.3 × 103 M−1s−1; koff was 7.13 ± 0.9 × 10−5 s−1, and the Kd was 47.6 ± 7 nM. The kon for binding
of tPA to KD1-Y11T/L17R-KCOOH was 2.91 ± 0.4 × 103 M−1s−1; koff was 1.05 ± 0.7 × 10−4 s−1, and the
Kd was 35.4 ± 5 nM.J. Clin. Med. 2020, 9, x FOR PEER REVIEW 10 of 25 
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(A) DIP-δplasmi binding to KD1-Y11T/L17R-KCOOH. DIP-δplasmin was coupled to the CM5
chip by the amine coupling method, and n immobilization level of 734 response units (RU) was
attained f r the bound protein. Five concentrations (0.1 µ , 0.3 , 0.5 µM, 0.75 µM and µM) of
D1-Y11T/L17R-KCOOH were used, and 6 min associati n and 10 min dissociati n times (flow rat
of 10 µL/min) were em l ye . Details are p ovided in the Experimental section. (B) tPA binding
to KD1-Y11T/L17R-KCOOH. The tPA was couple to the CM5 chip, and an immobilization level of
1182 RU was attained for the bou d pr tein. Five concentrations of KD1-Y11T/L17R-KCOOH (0.1 ,
0.3 µM, 0.75 µM, 1 µM and 2 µM) were used. The analyte association and dissociation protocols were
the same as in panel (A). Experiments in panel (A) and panel (B) were performed in duplicate. Each
data set was then use to calc late kon, koff and Kd values and to obtain the m an ± SD values provided
in the text.
3.5. Fibrinolysis (Clot Lysis) Assay
These experiments were performed to compare the effectiveness of KD1-L17R-KCOOH,
KD1-Y11T/L17R-KCOOH, and aprotinin at inhibiting tPA-induced plasma clot fibrinolysis. The addition
of IIa to NPP caused fibrin formation, which was reflected by an increase in OD405 (curve IIa,
Zero tPA, Figure 5A−C). The simultaneous addition of tPA caused initial clot formation followed by
the dissolution of fibrin induced by tPA-mediated conversion of plasminogen to plasmin (curve IIa,
tPA; Figure 5A−C); the midpoint of fibrinolysis was between 6 and 7 min in each case in the absence of
a fibrinolytic inhibitor. All three agents inhibited fibrinolysis in a dose-dependent manner. Max OD405,
OD405 at 60 min and the time to reach fibrinolysis midpoint at each concentration of the inhibitor
used are provided in Table 2. Max OD405 did not differ between the inhibitors or with different
concentrations of inhibitor. Max OD405 reflected the IIa-induced strength of the fibrin clot formed,
which was achieved rapidly before subsequent lysis commenced by tPA generated plasmin at the clot
site. Thus, it was anticipated that max OD405 at different concentrations of each inhibitor used would
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be similar. Further, OD405 at 60 min indicated the extent of fibrinolysis, which was relatively similar
for each inhibitor at lower concentrations; however, it was more reduced for KD1-L17R-KCOOH and
moderately reduced for KD1-Y11T/L17R-KCOOH as compared to aprotinin at higher concentrations
(Figure 5, Table 2).
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0 + No tPA 1.55 ± 0.10 1.69 ± 0.13 1.64 ± 0.14 1.49 ± 0.11 1.63 ± 0.11 1.60± 0.21 >60 >60 >60
0 + tPA 1.47 ± 0.15 1.42 ± 0.17 1.48 ± 0.20 0.88 ± 0.15 0.86 ± 0.12 0.86 ± 0.11 7 ± 1 7 ± 1 7 ± 1
0.5 + tPA 1.48 ± 0.11 1.54 ± 0.14 1.54 ± 0.15 0.85 ± 0.14 0.85 ± 0.13 0.85 ± 0.10 10 ± 0.76 13 ± 1.25 13 ± 0.8
1.0 + tPA 1.56 ± 0.10 1.54 ± 0.11 1.63 ± 0.13 0.87 ± 0.11 0.84 ± 0.12 1.04 ± 0.14 13 ± 0.5 27 ± 1.1 27 ± 1.5
1.5 + tPA 1.61 ± 0.13 1.58 ± 0.13 1.62 ± 0.08 0.90 ± 0.14 0.86 ± 0.15 1.22 ± 0.12 17 ± 1.0 43 ± 1.6 >60
2.0 + tPA 1.58 ± 0.09 1.62 ± 0.10 1.35 ± 0.06 1.50 ± 0.09 >60 >60
3.0 + tPA 1.74 ± 0.05 1.71 ± 0.10 1.68 ± 0.07 0.80 ± 0.13 1.57 ± 0.08 1.56 ± 0.05 31 ± 1.75 >60 >60
4.0 + tPA 1.62 ± 0.11 0.92 ± 0.05 43 ± 1
5.0 + tPA 1.69 ± 0.08 1.13 ± 0.06 55 ± 1.5
Importantly, KD1-L17R-KCOOH increased the fibrinolysis midpoint from ~7 min to ~10 min at
0.5 µM, ~13 min at 1 µM, ~17 min at 1.5 µM, ~31 min at 3 µM, ~43 min at 4 µM and ~55 min at 5 µM,
respectively (Figure 5A, Table 2). KD1-Y11T/L17R-KCOOH increased the fibrinolysis midpoint from
~7 min to ~12 min at 0.5 µM, ~28 min at 1 µM, ~43 min at 1.5 µM and > 60 min at 2 µM, as well as at
3 µM, respectively (Figure 5B, Table 2). Aprotinin increased the midpoint of fibrinolysis from ~7 min
to ~13 min at 0.5 µM, ~40 min at 1 µM, and > 60 min at 1.5 µM as well as at >1.5 µM concentration,
respectively (Figure 5C, Table 2). Cumulatively, the statistical analyses presented in Figure 6 reveal
that KD1-Y11T/L17R-KCOOH was more effective in increasing the fibrinolysis midpoint as compared to
KD1-L17R-KCOOH, and aprotinin was slightly more effective than KD1-Y11T/L17R-KCOOH.
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dyn/cm2 and 100% clot lysis occurred within 30 min (Table 3). At >1.5 µM plasmin, no clot formation 
was observed. Figure 7B–F illustrate the average TEG traces at different concentrations (1 µM to 7.5 
µM) of KD1-WT, KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH and aprotinin on clot formation and lysis 
in the presence of 1.5 µM plasmin. The data indicate that all antifibrinolytics tested improved the clot 
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and aprotinin at various concentrations used ((A), 0.5 µM; (B), 1.0 µM; (C), 1.5 µM; and (D), 3.0 µM) in
the plasm clot lysis assay. Bar graphs are presented displaying time (minutes) to reach fibrinolysis
midpoints with KD1-L17R- COOH, KD1-Y11T/L17R-KCOOH and aprotinin at the indicated c c tr ti .
Conce trati f i i it r i i icated for each panel. All experiments w re performed
in triplicate and the mean ± SD values are presented. ote: The * represe ts significant
difference from all other agents listed. The * indicates p < 0.05.
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3.6. Thromboelastography
Thromboelastography experiments were performed to evaluate the effect of KD1-WT [31],
KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH, aprotinin and EACA on the plasmin induced lysis of clot
formed in whole blood by the addition of CaCl2. These data are presented in Figure 7 and summarized
in Table 3. Figure 7A shows the TEG traces at different concentrations of plasmin on the clot formation
initiated with CaCl2. In the absence of plasmin, the average maximal amplitude (MA) achieved was
~47 mm with a shear elastic modulus strength G of ~4620 dyn/cm2, and no clot lysis could be detected at
60 min (LY60 < 0.1%). At 1.5 µM plasmin, the MA reached was ~7 mm with a G value of ~401 dyn/cm2
and 100% clot lysis occurred within 30 min (Table 3). At >1.5 µM plasmin, no clot formation was
observed. Figure 7B–F illustrate the average TEG traces at different concentrations (1 µM to 7.5 µM) of
KD1-WT, KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH and aprotinin on clot formation and lysis in the
presence of 1.5 µM plasmin. The data indicate that all antifibrinolytics tested improved the clot firmness
(MA) and shear strength (G) and inhibited fibrinolysis in a concentration dependent manner (Table 3).
Notably, at inhibitor concentrations of 5µM (corresponding to the high dose of the Hammersmith regime,
which is the established clinical administration regimen for aprotinin) [33], KD1-Y11T/L17R-KCOOH
improved the clot strength MA to ~80% (37.5 mm) and G to ~65% (~3004 dyn/cm2, whereas aprotinin
improved the MA to ~69% (32.9 mm) and G to ~53% (~2453 dyn/cm2). However, LY60 of ~12% was
observed with KD1-Y11T/L17R-KCOOH compared to 0.2% with aprotinin. At 7.5 µM concentration,
both KD1-Y11T/L17R-KCOOH and aprotinin had similar MA (~83% and ~80%) and G (~70% and ~65%),
as well as LY60 (each 0.2%). EACA also improved the MA, G and LY60 in a dose dependent manner
(Figure 7G). However, at 3-mM concentration of EACA, i.e., the dose used in the clinical setting,
it improved the MA and G only up to ~67% and ~50% respectively. Cumulatively, the TEG data
indicate that EACA is not as effective as KD1-Y11T/L17R-KCOOH or aprotinin in restoring the MA and
G. Furthermore, KD1-WT and KD1-L17R-KCOOH were also not as effective as KD1-Y11T/L17R-KCOOH
or aprotinin. Importantly, at higher concentrations (≥7.5 µM), KD1-Y11T/L17R-KCOOH restored the
MA and G, and inhibited fibrinolysis similar to aprotinin.
Multiple comparison analyses performed on the concentration-dependent enhancement of
maximal amplitude (MA), shear elastic modulus strength (G) and LY60 by KD1-WT, KD1-L17R-KCOOH,
KD1-Y11T/L17R-KCOOH and aprotinin in TEG experiments are presented in Figures 8–10. At 1 µM
inhibitor concentration, the MA was not significantly different between the control and each Kunitz
inhibitor except the KD1-WT (Figure 8A). At 2 or 3 µM inhibitor concentrations, the MA enhancement
by aprotinin was statistically significant (p < 0.05) as compared to KD1-WT, KD1-L17R-KCOOH and
KD1-Y11T/L17R-KCOOH (Figure 8B,C). Above 3 µM, enhancement in MA was statistically not different
for KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH and aprotinin; however, it was significantly lower for
KD1-WT (Figure 8D,E). For EACA, Student’s t-test was performed to compare MA between control
and each EACA concentration tested (Figure 8F). At 500 µM, 1000 µM or 3000 µM EACA concentration,
the MA enhancement was statistically significant as compared to the control.
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Figure 7. Thromboelastograms illustrating the dose-response analysis of KD1-WT, KD1-L17R-KCOOH,
KD -Y11T/L17R-KCOOH, aprotinin and A. All experiments contained citrated whole blood (300 µL),
1.5 µM plasmin and 10 mM CaCl2. The antifibrinolytic agent was added first to the blo d, which was
then spiked with 1.5 µM plasmin and 10 mM Ca l2. The clot formation and lysis were monitored
for 180 min. Control experiments were performed in the presence or absence of plasmin without
any antifibrinolytic agent. (A) Plasmin effect of clot formation and fibrinolysis. Citrated whole blood
(300 µL) was spiked with various concentrations of plasmin (0–3 µM) and 10 mM CaCl2. The clot
formation and lysis was monitored for 180 min. Effect of 1 µM (B), 2 µM (C), 3 µM (D), 5 µM (E) and
7.5 µM (F) of KD1-WT, KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH and aprotinin on clot formation
and fibrinolysis using 1.5 µM plasmin. (G) Effect of 200 µM to 3000 µM EACA on clot formation and
fibrinolysis using 1.5 µM plasmin. Pm, plasmin; NHB, Normal human blood.
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Inhibitor MA (mm) G (dyn/cm
2) LY30 (%) LY60 (%)
0 µM 7.18 ± 0.17 411 ± 13.1 100 100
1 µM
KD1-WT 1.45 ± 0.28 79.05 ± 5.7 100 100
KD1-L17R-KCOOH 6.45 ± 0.49 328.75 ± 9.3 10.1 ± 0.32 28.4 ± 0.49
KD1-Y11T/L17R-KCOOH 7.82 ± 0.45 414.3 ± 10.1 0.75 ± 0.6 13.7 ± 0.64
Aprotinin 12.15 ± 0.78 678.6 ± 5.4 0 0.30 ± 0.08
2 µM
KD1-WT 2.23 ± 0.25 107.9 ± 3.2 100 100
KD1-L17R-KCOOH 11.84 ± 0.33 598.7 ± 6.1 0 4.95 ± 0.35
KD1-Y11T/L17R-KCOOH 11.88 ± 0.41 611.7 ± 5.8 0 0.45 ± 0.07
Aprotinin 18.19 ± 0.43 1050.5 ± 8.3 0 0
3 µM
KD1-WT 3.49 ± 0.41 180.15 ± 7.1 100 100
KD1-L17R-KCOOH 12.34 ± 0.61 683.2 ± 9.8 0 19.9 ± 0.42
KD1-Y11T/L17R-KCOOH 16.03 ± 0.31 879.3 ± 15.6 0 2.2 ± 0.28
Aprotinin 19.78 ± 0.68 1174.1 ± 16.7 0 0
5 µM
KD1-WT 13.90 ± 0.28 817.95 ± 10.1 6.5 ± 0.7 22.4 ± 0.92
KD1-L17R-KCOOH 31.35 ± 0.76 2315.15 ± 49.4 0 12.3 ± 0.50
KD1-Y11T/L17R-KCOOH 37.48 ± 0.40 3004.75 ± 50.6 0 12.2 ± 0.49
Aprotinin 34.04 ± 0.77 2453.2 ± 36.9 0 0.2 ± 0.04
7.5 µM
KD1-WT 11.73 ± 0.38 820.1 ± 21.3 0 0
KD1-L17R-KCOOH 33.93 ± 0.88 2527.5 ± 49.6 0 5 ± 0.52
KD1-Y11T/L17R-KCOOH 40.37 ± 1.22 3292.45 ± 35.0 0 0.2 ± 0.03
Aprotinin 38.45 ± 0.78 3078.1 ± 44.9 0 0.2 ± 0.02
200 µM EACA 3.20 ± 0.71 153.25 ± 9.8 0 0
500 µM EACA 13.15 ± 0.64 747.75 ± 14.8 0 0
1000 µM EACA 16.40 ± 0.28 1070.1 ± 35.0 0 16.8 ± 0.35
3000 µM EACA 32.60 ± 0.71 2388.0 ± 49.6 0 0.6 ± 0.04
NHB, Normal human blood; MA, maximal amplitude (maximal clot strength); G, shear strength; LY30, Percent lysis
observed at 30 min after clot formation; LY60, Percent lysis observed at 60 min after clot formation. Mean ± SD
are provided.
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L17R-KCOOH, KD1-Y11T/L17R-KCOOH, aprotinin and EACA at different concentrations. Bar graphs 
represent the MA achieved with KD1-WT, KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH, aprotinin and 
EACA at different concentrations. Panel A, 1 µM; panel B, 2 µM; panel C, 3 µM; panel D, 5 µM; panel 
E, 7.5 µM; and panel F, 200 M to 3000 M EACA. All experiments were performed in duplicate and 
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all other agents listed. The * indicates p < 0.05. 
Figure 8. Comparison of maximal amplitude (MA) from the TEG experiments for KD1-WT,
KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH, aprotinin and EACA at different concentrations.
Bar graphs represent the MA achieved with KD1-WT, KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH,
aprotinin and EACA at different concentrations. Panel (A), 1 µM; panel (B), 2 µM; panel (C), 3 µM;
panel (D), 5 µM; panel (E), 7.5 µM; and panel (F), 200 µM to 3000 µM EACA. All experiments were
performed in duplicate and the mean ± SD values are presented. Note: The * without bar represents
significant difference from all other agents listed. The * indicates p < 0.05.
Notably up to 3 µM, aprotinin enhanced G significantly compared to the KD1-based inhibitors
(Figure 9A–C). Surprisingly, at 5 and 7.5 µM inhibitor concentrations, the enhancement of G by
KD1-Y11T/L17R-KCOOH was significantly higher as compared to the other inhibitors (Figure 9D,E).
This observed improvement in clot shear strength G for KD1-Y11T/L17R-KCOOH versus aprotinin
might possibly have been to FXIa and kallikrein inhibition by aprotinin versus essentially no inhibition
by KD1-Y11T/L17R-KCOOH. Additionally, multiple comparison analyses of LY60 for each inhibitor at
selected concentrations are presented in Figure 10. At 1 or 5 µM, aprotinin was significantly better
at preventing fibrinolysis compared to each KD1 inhibitor, whereas KD1-WT was inferior to each
inhibitor at all concentrations tested. At 2 or 3 µM, KD1-Y11T/L17R-KCOOH and aprotinin were
superior to KD1-L17R-KCOOH and no LY60 was observed with any inhibitor at 7.5 µM concentration.
Overall, it would appear that aprotinin and KD1-Y11T/L17R-KCOOH were superior to other inhibitors
at inhibiting fibrinolysis in the TEG experiments.
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Figure 10. Comparison of LY60% (TEG experiments) for KD1-WT, KD1-L17R-KCOOH, KD1-
Y11T/L17R-KCOOH and aprotinin at different concentrations. Bar graphs showing the percent lysis at 
60 min are depicted. Panel A, 1 M; panel B, 2 M; panel C, 3 M; and panel D, 5 M. All experiments 
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Figure 9. Comparison of shear elastic modulus strength (G, TEG experiments) for KD1-WT,
KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH, aprotinin and EACA at different concentrations.
Bar graphs represent the ‘G’ achieved with KD1-WT, KD1-L17R-KCOOH, KD1-Y11T/L17R-KCOOH,
aprotinin and EACA at different concentrations. Panel (A), 1 µM; panel (B), 2 µM; panel (C), 3 µM;
panel (D), 5 µM; panel (E), 7.5 µM; and panel (F), 200 µM to 3000 µM EACA. All experiments were
performed in duplicate and the mean ± SD values are presented. Note: The * without bar represents
significant difference from all other agents listed. The * indicates p < 0.05 and ** indicates p < 0.01.
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3.7. Cell Toxicity Studies
Here, we wanted to gain insights into the potential toxicity of KD1-Y11T/L17R-KCOOH compared
with aprotinin and the currently used antifibrinolytic agents EACA and TXA. Patients are typically
treated with antifibrinolytic agents via intravenous injections while undergoing major surgery, or via
external use in trauma situations. We therefore tested cytotoxicity in endothelial cells and skin fibroblasts,
the cells most likely to be exposed to therapeutic doses of KD1-Y11T/L17R-KCOOH. The plasma half-life
of TXA in humans, rats and dogs is ~120 min [48]. The half-life each of the two KD1 variant homologs
(aprotinin and Ecallantide) is also ~120 min [49,50] in humans, whereas the half-life of aprotinin in
mice, rats or dogs is ~70 min [51]. The half-life of each KD1 variant is not known, but might be short,
and will be determined in future research. Since the half-life of each of the antifibrinolytic agents
in vivo is short, infusion is usually continuous throughout the duration of surgery. Treatment duration
was therefore set at 24 h and the chosen dose range included the equivalent of ~3x the clinical dose for
each of the reagents tested.
A resazurin assay of HUVEC treated with KD1-Y11T/L17R-KCOOH or aprotinin for 24 h did not
result in any significant change in cell viability compared to cells treated with phosphate buffer control
over the entire dose range from 0.1–30 µM (Figure 11A). The same result was obtained after treatment
with EACA (dose range 1–60 mM) and TXA (dose range 0.2–30 mM). Cell viability was equally
unchanged in primary human skin fibroblasts (Figure 11B), indicating that none of the antifibrinolytic
agents tested caused measurable cytotoxicity within the 24 h duration of treatment.
Viability is the endpoint of cytotoxicity. Thus, we examined the induction of apoptosis resulting
from caspase activation. Caspase 3/7 assays were performed in HUVEC cells following treatment
with antifibrinolytic agents (Figure 11C). Caspase 3/7 activities significantly increased when the cells
were treated with the two higher concentrations of TXA (10 mM and 30 mM) and, to a lesser extent,
after exposure with EACA (20 mM and 60 mM). In contrast to TXA and EACA, KD1-Y11T/L17R-KCOOH
and aprotinin did not induce caspase activity above baseline at all concentrations. Taxol was included
as a positive control. None of the antifibrinolytics increased caspase activity above baseline in primary
fibroblasts across all doses.
To confirm the above results using a different assay, we performed CellTox green cytotoxicity
assays in HUVEC cells and primary fibroblasts. The CellTox green dye binds DNA, resulting in
fluorescent staining only when membrane integrity has been compromised. No significant increase in
the percentage of fluorescent cells could be detected 24 h after treatment with the highest dose (30 µM)
of KD1-Y11T/L17R-KCOOH in the endothelial cells (Figure 11D) or in the fibroblasts (Figure 11E).
Cell cytotoxicity also did not increase significantly over baseline when cells (HUVEC or fibroblasts)
were treated with other antifibrinolytic agents. For brevity, the data for aprotinin, TXA and EACA are
not shown.
In summary, 24 h treatment of HUVEC cells and primary human fibroblasts with 0.1–30 µM
KD1-Y11T/L17R-KCOOH or aprotinin did not decrease viability, induce apoptosis or show any sign
of cytotoxicity. However, TXA and EACA induced apoptosis (cell death) at higher concentrations in
HUVEC cells, as inferred from an increase in caspase 3/7 activity.
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Figure 11. Toxicity studies of KD1-Y11T/L17R-KCOOH, aprotinin, EACA and TXA in primary endothelial
cells or fibrobla ts. (A) C ll viability in HUVE and (B) in prima y human skin fibroblasts. Cells were
treated with KD1-Y11T/L17R-KCOOH, aprotinin, EACA, or TXA for 24 h at the indicated concentrations.
Fluorescence intensity is plotted against concentration of each antifibrinolytic inhibitor. Note that,
fluorescence intensity is proportional to rel ive cell number. Data po ts represent means from three
independent experiments ± SEM. In each case, cell viability appears to be not significantly different
from the untreated cells (p > 0.05). (C) Apoptosis in HUVEC cells. HUVEC cells were either untreated
or treated with KD1-Y11T/L17R-KCOOH, aprotinin, EACA or TXA for 24 h at increasing concentrations
(C1–C4). Taxol was included as a positive control. Luminescence, displayed as relative light units
(RLU), is proportional to caspase-3/7 activity. EACA and TXA, but not KD1-Y11T/L17R-KCOOH
or aprotinin show significantly increased caspase activity at concentrations used in C3 and C4
compared to the untreated cells. Data are mean ± SD from three experiments. (* p < 0.05, ** p < 0.01,
*** p < 0.001). (D) Absence of cytotoxicity in HUVEC and (E) primary human skin fibroblasts with
KD1-Y11T/L17R-KCOOH. Cells were either untreated or treated with 30 µM KD1-Y11T/L17R-KCOOH
J. Clin. Med. 2020, 9, 3684 20 of 24
for 24 h. Taxol (0.05 µM) was included as positive control. FITC: CellTox green dye binds to
DNA when membrane integrity has been compromised. Fluorescent signal indicates cytotoxicity.
DAPI: nuclear stain, binds to all nuclei. Representative images of one of three independent experiments
performed are shown. Graph depicts quantification of cytotoxicity assay. Percent of green cells out
of all cells per field were calculated. Mean ± SD value of 4 fields per treatment group are displayed
(** p < 0.01, **** p < 0.0001).
4. Discussion
Earlier, based on structural information and S2′-subsite specificity, we designed a 73-residue
Kunitz domain plasmin inhibitor from TFPI-2 KD1 [32]. The KD1-WT inhibits plasmin as well
as pKLK, FXIa and FVIIa/TF with comparable affinities, whereas KD1-L17R inhibits only plasmin.
The change in residue 17 (BPTI numbering) from Leu to Arg made the KD1-L17R specific for
plasmin and dramatically reduced pKLK and FXIa inhibition. As compared to the current 60-residue
KD1-L17R-KCOOH, the previously expressed KD1-L17R had 13 additional residues (9 from the TFPI-2
sequence and 4 from the IIa cleavage site) at the N-terminus and four (VPKV) at the C-terminus,
apart from the core Kunitz domain. Although these additional residues do not interfere with KD1-L17R
function, they are flexible and could be disordered as inferred from the crystal structure of the
KD1-WT [36].
Therefore, a new 60-residue KD1-L17R-KCOOH mutant was expressed and its inhibition profile
was characterized. Since none of the active site inhibition profiles of 60-residue KD1-L17R-KCOOH had
changed from the previously expressed 73-residue KD1-L17R, it was predicted that KD1-L17R-KCOOH
would be very effective in reducing blood loss and could be comparable to aprotinin in the two mouse
bleeding models (liver laceration and tail-amputation) tested [32,41,52].
The 73-residue KD1-L17R has IEKVPKV at the C-terminus and valine could be removed by
extended incubation with IIa [41]. The removal of Val residue at the C-terminus generated a C-terminal
lysine that made the KD1-L17R a dual reactive inhibitor of fibrinolysis by inhibiting the plasmin active
site, as well as plasminogen activation [41]. Moreover, extended incubation with IIa resulted in a
heterogeneous population of KD1-L17R with different N-terminal residues [41]. The structural analysis
of the modeled complex of plasmin and KD1-L17R indicated that changing residue Tyr11 to Thr
would be beneficial for plasmin inhibition. Threonine in KD1-Y11T/L17R-KCOOH made an additional
hydrogen bond with residue Q192 of plasmin (Figure 12A). Interestingly, 73-residue KD1-L17R
contained two lysine residues at the C-terminal segment (IEKVPKV), and either of them could serve as
a C-terminal residue. Further, the modeling of 60-residue KD1-L17R-KCOOH with the C-terminus IEK
sequence showed that it will enhance the interactions with the kringle domains of plasminogen and
tPA (Figure 12B). Compared to the VPK sequence, the IEK sequence had two additional interactions
arising from Arg57 and Glu59 of Kunitz domain with plasmin kringle residues Glu151 and Arg153,
respectively (Figure 12B). Similar interactions are predicted to occur with the kringle domain of tPA as
well. For these reasons, the 60-residue double mutant (KD1-Y11T/L17R-KCOOH) was expressed with
the IEK C-terminus.
The newly E. coli expressed KD1-L17R-KCOOH and KD1-Y11T/L17R-KCOOH with C-terminal IEK
sequence both contained His6-tag and the enterokinase cleavage sequence; however, these additional
residues could not be removed by enterokinase. Similar to the 73-residue KD1-L17R construct,
the presence of additional residues did not affect the inhibition properties of KD1-L17R-KCOOH and
KD1-Y11T/L17R-KCOOH mutants. Therefore, the 60-residue KD1-Y11T/L17R-KCOOH was expressed in
P. pastoris. As predicted, KD1-Y11T/L17R-KCOOH inhibited plasmin with increased affinity as compared
to KD1-L17R-KCOOH (0.59 nM vs. 0.9 nM). Further, the 60-residue KD1-Y11T/L17R-KCOOH with IEK
C-terminal bound to the kringle domains of tPA and plasmin with increased affinity (35 nM to 50 nM)
Figure 5 as compared to the KD1-L17R-KT with C-terminal VPK (250 nM to 300 nM) [41]. The modest
increase in plasmin active site inhibition and significantly improved affinity for kringle domains of
plasminogen and tPA was reflected in strong inhibition of fibrinolysis by KD1-Y11T/L17R-KCOOH
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in plasma clot lysis assay (Figure 4B) and in restoring MA, G and LY60 in the TEG experiments
(Figure 7B–F).
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Figure 12. Modeled complexes of KD1-Y11T/L17R-KCOOH interaction with plasmin. (A) Modeled
interactions of KD1-Y11T/L17R-KCOOH with the plasmin protease domain. The electrostatic surface
of the plasmin protease domain and a cartoon representation of the KD1-Y11T/L17R-KCOOH (yellow)
are depicted. The P1 (Arg15), P5 (Thr11) and P2′ (Arg17) residues of KD1-Y11T/L17R-KCOOH
interactions with plasmin are shown in stick representation. In the electrostatic surface, blue represents
positive, red represents negative, and white represents neutral charge. (B) Modeled interaction of
KD1-Y11T/L17R-KCOOH with plasmin kringle domain. The electrostatic surfac of the plasminogen
kringle domain1 and a cartoon representati n of the KD1-Y11T/L17R-KCOOH (yellow) are depicted.
The residues that form hydrogen bonds and salt bridges (shown as dashed lines) between the kringle
domain and KD1-Y11T/L17R-KCOOH are shown in stick representation. The carbon atoms are shown
in green for the kringle domain and yellow for KD1-Y11T/L17R-KCOOH. As in (A) oxygen atoms
are shown in red and nitrogen atoms in blue. The KD1-Y11T/L17R-KCOOH residues are labeled with
the suffix I. In the electrostatic surface, blue represents positive, red represents negative, and white
represents neutral charge.
The KD1 double mutant (KD1-Y11T/L17R-KCOOH) made in P. pastoris is a compact, homogeneous
and an effective specific plasmin inhibitor of human origin. The properties of KD1-Y11T/L17R-KCOOH
were comparable to aprotinin in plasmin inhibition assay, plasma clot lysis assay and in the
TEG experiments. Moreover, KD1-Y11T/L17R-KCOOH did not inhibit pKLK, FXIa and FVIIa/sTF.
Furthermore, KD1-Y11T/L17R-KCOOH did not induce any measurable cytotoxicity in primary
endothelial cells or skin fibroblasts (Figure 11). However, TXA and EACA caused apoptosis
in these cells at higher concentrations, which could be achieved during renal clearance of these
antifibirinolytics. These results are in agreement with KD1-L17R-KT single mutant, which did not
induce renal toxicity, seizures or any detectable histopathologic changes in the mouse kidney [32].
In case of aprotinin, its acidic nature and pKLK inhibition results in altered renal activity, which leads
to kidney damage [32,53]. The current antifibrinolytics EACA and TXA cause seizures by inhibiting
glycine receptors [54]. Since lysine analogs are not as effective as aprotinin, the higher doses of EACA
and TXA increase the risk of renal failure, as these agents reach very high concentrations during
clearance by glomerular filtration [55,56]. The KD1Y11T/L17R-KCOOH data from the current study are
encouraging; however, the compound needs to be evaluated in suitable animal bleeding models before
it can be considered for clinical trials.
5. Patents
S.P. Bajaj has a patent pending on the KD1-L17R and related molecules.
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